Increased Proportion of Colorectal Cancer in Patients With Ulcerative Colitis Undergoing Surgery in the Netherlands.

"CONFLICTS OF INTEREST Guarantor of the article: Christianne J. Buskens, MD, PhD. Specific author contributions: L.H., W.A.B., and C.J.B.: created the study concept and design. L.H. and H.H.: collected the data and conducted the analyses. L.H.: drafted the manuscript. All authors participated in the critical revision of the manuscript for intellectual content and approved the final version. Financial support: This study was supported by a research grant from the European Crohn's and Colitis Organization. Potential competing interests: L.H., H.H., H.J.S., and A.M. have no competing interests. G.R.D. has served as advisor for AbbVie, Ablynx, Active Biotech AB, AgomAb Therapeutics, Alimentiv, Allergan, Alphabiomics, Amakem, Amgen, AM Pharma, Applied Molecular Therapeutics; Arena Pharmaceuticals, AstraZeneca, Avaxia, Biogen, Bristol Myers Squibb/Celgene, Boehringer Ingelheim, Celltrion, Cosmo, DSM Pharma; Echo Pharmaceuticals, Eli Lilly, Engene, Exeliom Biosciences; Ferring, DrFALK Pharma, Galapagos, Genentech/Roche, Gilead, GlaxoSmithKline, Gossamerbio, Pfizer, Immunic, Johnson and Johnson, Kintai Therapeutics, Lument, Lycera, Medimetrics, Takeda, Medtronic, Mitsubishi Pharma, Merck Sharp & Dohme, Mundipharma, Nextbiotics, Novo Nordisk, Otsuka, PhotoPll, ProciseDx, Prodigest, Prometheus Laboratories/Nestle, Progenity, Protagonist, RedHill, Salix, Samsung Bioepis, Sandoz, Seres/Nestec/Nestle, Setpoint, Shire, Teva, Tigenix, Tillotts, Topivert, Versant, and Vifor. Received speaker fees from AbbVie, Biogen, Ferring, Galapagos/Gilead, Johnson and Johnson, Merck Sharp & Dohme, Mundipharma, Norgine, Pfizer, Samsung Bioepis, Shire, Millennium/Takeda, Tillotts, and Vifor. S.V. has received grants from AbbVie, J&J, Pfizer, Galapagos, and Takeda and has received consulting and/or speaking fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Dr. Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, and Zealand Pharma. A.D. has no competing interests. W.A.B. has received research funding from VIFOR; served as a consultant for Takeda and Braun; and received speakers fees from Takeda, Johnson, Braun, and Medtronic. C.J.B. has an unrestricted grant from Boehringer Ingelheim and Roche AND has received consultancy fees or speaker's honoraria from AbbVie, Merck Sharp & Dohme, Tillotts, Janssen, and Takeda. Study HighlightsWHAT IS KNOWN✓ Patients with ulcerative colitis have an increased risk of colorectal cancer (CRC).✓ Improved disease control and surveillance programs are suggested to reduce the risk of CRC.WHAT IS NEW HERE✓ There is an indication shift for surgery from therapy-refractory disease to CRC.✓ Disease duration at the time of colorectal surgery increased.✓ The proportion of patients diagnosed with advanced malignancy did not change over time."

"Financial support: This study was supported by a research grant from the European Crohn's and Colitis Organization."